# A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Pr

Source: https://onco.cc/trials/nct07192614/  
OnCo record `nct07192614` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD6621 in prostate cancer, run by AstraZeneca, now recruiting.

## Summary

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT07192614 by AstraZeneca, with 52 participants planned, started 2025-09-30 and due to reach its primary completion in 2029-03-29. Interventions recorded: AZD6621. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07192614
- Phase: 1/2
- Setting: A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer
- Sponsor: AstraZeneca
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT07192614: https://clinicaltrials.gov/study/NCT07192614

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [AZD6621](https://onco.cc/drugs/azd6621/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07192614.json